Analyst Summary
Gujarat Inject (Kerala) Ltd operates in the Pharmaceuticals segment, NSE: GUJINJEC | BSE: 524238, current market price is ₹82.10, market cap is 120 Cr.. At a glance, stock P/E is 481, ROE is 11.0 %, ROCE is 13.5 %, book value is 6.93, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹75.34, around 8.2% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹19 Cr versus the prior period change of 229.0%, while latest net profit is about ₹1 Cr with a prior-period change of 1,175.0%. The 52-week range shown on this page is 82.1/17.0, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisGujarat Inject (Kerala) Ltd. is a Public Limited Listed company incorporated on 07/01/1991 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN)…
This summary is generated from the stock page data available for Gujarat Inject (Kerala) Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.
Investment Snapshot
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.
Share Price and Basic Stock Data
Last Updated: April 2, 2026, 4:44 am
| PEG Ratio | 142.91 |
|---|
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Inject (Kerala) Ltd | 120 Cr. | 82.1 | 82.1/17.0 | 481 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Brooks Laboratories Ltd | 131 Cr. | 44.5 | 166/36.3 | 6.07 | 39.3 | 0.00 % | 9.93 % | 12.2 % | 10.0 |
| Achyut Healthcare Ltd | 132 Cr. | 5.62 | 6.80/3.00 | 308 | 1.34 | 0.00 % | 2.26 % | 1.77 % | 1.00 |
| Lactose (India) Ltd | 106 Cr. | 84.2 | 137/76.0 | 21.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| Alpa Laboratories Ltd | 106 Cr. | 50.2 | 120/46.0 | 8.95 | 92.0 | 0.00 % | 15.0 % | 11.5 % | 10.0 |
| Industry Average | 19,815.15 Cr | 1,053.84 | 53.84 | 201.20 | 0.39% | 16.35% | 15.16% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.10 | -0.00 | 0.15 | -0.00 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 | 1.58 | 1.63 |
| Expenses | 0.10 | 0.02 | 0.11 | -0.00 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 | 1.55 | 1.72 |
| Operating Profit | -0.00 | -0.02 | 0.04 | -0.00 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.10 | 0.03 | -0.09 |
| OPM % | -0.00% | 26.67% | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | 1.90% | -5.52% | ||
| Other Income | -0.00 | 0.03 | -0.00 | 0.02 | 0.04 | -0.00 | -0.00 | 0.17 | -0.00 | 0.01 | -0.00 | 0.06 | 0.14 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | -0.00 | 0.01 | 0.04 | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.10 | 0.10 | 0.09 | 0.05 |
| Tax % | -0.00% | 25.00% | -0.00% | -0.00% | 20.00% | 23.53% | 14.08% | 25.00% | 30.00% | 20.00% | 22.22% | 20.00% | |
| Net Profit | -0.00 | 0.01 | 0.03 | 0.01 | -0.00 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 | 0.07 | 0.04 |
| EPS in Rs | -0.00 | 0.02 | 0.06 | 0.02 | -0.00 | 0.04 | 0.08 | 0.42 | 0.14 | 0.05 | 0.05 | 0.05 | 0.03 |
Last Updated: March 3, 2026, 9:24 am
Profit & Loss - Annual Report
Last Updated: February 27, 2026, 6:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 9.87 |
| Expenses | 0.00 | 0.00 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 9.74 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 0.13 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 1.32% | |||||
| Other Income | 0.00 | 0.00 | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.21 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 0.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | |||||
| Net Profit | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 0.25 |
| EPS in Rs | 0.00 | 0.00 | 4.69 | 0.02 | -0.04 | -0.02 | 0.00 | -0.22 | 0.00 | 0.08 | 0.07 | 0.70 | 0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Growth
Last Updated: September 5, 2025, 3:40 pm
Balance Sheet
Last Updated: March 3, 2026, 3:05 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.64 | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -4.48 |
| Borrowings | 2.55 | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | -0.00 | -0.00 | -0.00 |
| Other Liabilities | 0.38 | 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 1.55 |
| Total Liabilities | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Fixed Assets | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Total Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.55 | -2.86 | -0.56 | -0.56 | -0.66 | -0.62 | -0.60 | -0.81 | -0.78 | -0.98 | 0.05 | 1.07 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 167.06 | 137.76 | |||||
| ROCE % | 2.65% | 13.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.13 | 0.09 | 0.05 | 0.00 | -0.12 |
| Diluted EPS (Rs.) | 1.13 | 0.09 | 0.05 | 0.00 | -0.12 |
| Cash EPS (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Revenue From Operations / Share (Rs.) | 13.01 | 5.13 | 0.35 | 0.04 | 0.02 |
| PBDIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| Net Profit / Share (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| PBDIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBT Margin (%) | 6.58 | 1.81 | 31.93 | 13.05 | -911.24 |
| Net Profit Margin (%) | 5.34 | 1.42 | 23.62 | 9.77 | -911.24 |
| Return on Networth / Equity (%) | 10.15 | 0.96 | -4.90 | -0.25 | 0.00 |
| Return on Capital Employeed (%) | 12.53 | 1.23 | -14.62 | -0.64 | 22.60 |
| Return On Assets (%) | 8.51 | 0.95 | 13.53 | 3.41 | -599.51 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -0.54 | -0.47 | -0.47 |
| Total Debt / Equity (X) | 0.00 | 0.00 | -0.72 | -0.83 | -0.78 |
| Asset Turnover Ratio (%) | 1.85 | 1.29 | 0.94 | 0.54 | 0.72 |
| Current Ratio (X) | 5.15 | 40.77 | 0.10 | 0.04 | 0.02 |
| Quick Ratio (X) | 5.15 | 40.77 | 0.10 | 0.04 | 0.02 |
| Interest Coverage Ratio (X) | 861.55 | 237.71 | 1108.59 | 144.19 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 698.99 | 187.11 | 820.29 | 108.27 | 0.00 |
| Enterprise Value (Cr.) | 38.02 | 8.32 | 4.38 | 1.48 | 0.00 |
| EV / Net Operating Revenue (X) | 2.00 | 1.44 | 25.18 | 65.66 | 0.00 |
| EV / EBITDA (X) | 30.29 | 78.68 | 78.78 | 499.58 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 1.94 | 22.04 | 33.50 | 0.00 |
| Price / BV (X) | 3.80 | 1.31 | -4.57 | -0.86 | 0.00 |
| Price / Net Operating Revenue (X) | 2.00 | 1.94 | 22.08 | 33.70 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shop No. 15, K-Tower, Haveli Resi-Cum Plaza, Vadodra Gujarat 390014 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murli Nair | Chairman & Wholetime Director |
| Ms. Reena Mahatma | Non Executive Director |
| Mr. Rushiraj Zaverbhai Patel | Non Exe. & Ind. Director |
| Mr. Nileshbhai Vinubhai Rangholiya | Non Exe. & Ind. Director |
FAQ
What is the intrinsic value of Gujarat Inject (Kerala) Ltd and is it undervalued?
As of 23 April 2026, Gujarat Inject (Kerala) Ltd's intrinsic value is ₹75.34, which is 8.23% lower than the current market price of ₹82.10, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.0 %), book value (₹6.93), dividend yield (0.00 %), and 5-year EPS CAGR.
What is the current share price and 52-week range of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd is trading at ₹82.10 as of 23 April 2026, with a FY2026-2027 high of ₹82.1 and low of ₹17.0. The stock is currently near its 52-week high. Market cap stands at ₹120 Cr..
How does Gujarat Inject (Kerala) Ltd's P/E ratio compare to its industry?
Gujarat Inject (Kerala) Ltd has a P/E ratio of 481, which is above the industry average of 53.84. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.
Is Gujarat Inject (Kerala) Ltd financially healthy?
Key indicators for Gujarat Inject (Kerala) Ltd: ROCE of 13.5 % is moderate. Dividend yield is 0.00 %.
Is Gujarat Inject (Kerala) Ltd profitable and how is the profit trend?
Gujarat Inject (Kerala) Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹19 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows an improving trend.
Does Gujarat Inject (Kerala) Ltd pay dividends?
Gujarat Inject (Kerala) Ltd has a dividend yield of 0.00 % at the current price of ₹82.10. The company is currently not paying meaningful dividends.
